Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 31 July 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Increased risk of lymphoma in patients with ulcerative colitis treated With thiopurines

A study in the most recent issue of Gastroenterology examines the risk of lymphoma in patients with ulcerative colitis treated with thiopurines.

News image

There is controversy over whether the treatment of patients with ulcerative colitis with thiopurines increases their risk of lymphoma.

Dr Nabeel Khan and colleagues from Louisiana, USA evaluated the risk of lymphoma among thiopurine-treated patients with ulcerative colitis.

The researchers obtained nationwide data from the Veterans Affairs (VA) health care system from 2001 to 2011.

The team performed a retrospective cohort study, analyzing data on 36,891 patients from their date of diagnosis of ulcerative colitis in the VA health care system to a diagnosis of lymphoma or 2011.

Thiopurine exposure was assessed using the VA pharmacy database.

Incidence rates of lymphoma were 2.3 per 1000 person-years in those treated with thiopurines
Gastroenterology

Patients who developed lymphoma were identified based on ICD-9 codes and confirmed by manual chart review.

In total, 4734 patients with ulcerative colitis were treated with thiopurines for a median of 1 year.

The research team observed that lymphoma developed in 119 patients who had not been treated with thiopurines, 18 who were treated with thiopurines, and 5 who had discontinued treatment with thiopurines.

The incidence rates of lymphoma were 0.60 per 1000 person-years among patients who had not been treated with thiopurines, 2.3 among patients who were treated with thiopurines, and 0.28 among patients who had discontinued treatment with thiopurines.

The incidence rates of lymphoma during the first year, second year, third year, fourth year, and more than 4 years of thiopurine therapy were 0.9, 1.6, 1.6, 5, and 8.9 per 1000 person-years, respectively.

The age-, sex-, and race-adjusted hazard ratios of developing lymphoma were 4.2 while being treated with thiopurines, and 0.5 after discontinuing treatment with thiopurines compared with patients who had not been treated with thiopurines.

Dr Khan's team concludes, "Based on a retrospective, nationwide cohort study, patients with ulcerative colitis have a 4-fold increase in risk of lymphoma while being treated with thiopurines compared with patients who have not been treated with thiopurines."

"The risk increases gradually for successive years of therapy. Discontinuing thiopurine therapy reduces the risk of lymphoma."

Gastroenterology 2013: 145(5): 1007-1015.e3
30 October 2013

Go to top of page Email this page Email this page to a colleague

 29 July 2016 
Susceptibility loci for gallstone disease
 29 July 2016 
H. pylori clarithromycin resistance in the USA
 29 July 2016 
Tool to diagnose Helicobacter-negative gastritis
 28 July 2016 
HCV eradication in cirrhotic patients
 28 July 2016 
Hep B screening and immunosuppressive therapy
 28 July 2016 
Pancreatitis after ERCP
 27 July 2016 
Gluten exposure in patients with celiac disease
 27 July 2016 
Bleeding GI recurrence with aspirin use
 27 July 2016 
IBD during pregnancy
 26 July 2016 
Gut microbiota and IBD
 26 July 2016 
Neighborhood variation in the use of laparoscopy for colon cancer
 26 July 2016 
Post-infectious IBS after C. diff
 25 July 2016 
Antibiotic prophylaxis for open colectomies
 25 July 2016 
Steroids in eosinophilic esophagitis
 25 July 2016 
Prevention of post-ERCP pancreatitis
 22 July 2016 
Upper GI lesions at primary diagnosis in IBD
 22 July 2016 
Duodenal villous atrophy and celiac disease
 22 July 2016 
Fecal calprotectin and IBD
 21 July 2016 
Radiofrequency ablation in Barrett's
 21 July 2016 
HCV eradication and inflammation in cirrhotic patients
 21 July 2016 
Surveillance of Barrett's
 20 July 2016 
Nonselective β-blockers and survival in cirrhosis
 20 July 2016 
Adolescent body mass index and and colorectal cancer risk
 20 July 2016 
Genetic biomarkers and IBD treatment response
 19 July 2016 
Prevention of chemotherapy-induced nausea and vomiting
 19 July 2016 
Screening diabetic patients for NAFLD
 19 July 2016 
Longterm clinical follow-up of living liver donors
 18 July 2016 
Rectal neuroendocrine tumors
 18 July 2016 
Liver cancer prediction scores in Hep B
 18 July 2016 
Liver stiffness measurement in chronic liver disease
 15 July 2016 
Patient reported outcomes in celiac disease
 15 July 2016 
Tonsillectomy and IBD risk
 15 July 2016 
Trainee IBD education in the USA
 14 July 2016 
Screening for familial pancreatic cancer
 14 July 2016 
Fecal calprotection for IBD prognosis
 14 July 2016 
Perianal surgery risk in Crohn's
 13 July 2016 
Psychological comorbidity and postinfectious IBS
 13 July 2016 
Lung transplant outcomes in Hep C
 13 July 2016 
Graft selection strategy in living donor liver transplants
 12 July 2016 
Surveillance endoscopy in Barrett's esophagus
 12 July 2016 
Therapy for iron deficiency anemia in IBD
 12 July 2016 
Treatment of pediatric acute liver failure
 11 July 2016 
Transition to adulthood in celiac disease
 11 July 2016 
Disturbed sleep and IBS
 11 July 2016 
Factors that influence access to liver transplant
 08 July 2016 
Mortality and peptic ulcers
 08 July 2016 
Genetic risk score and body mass index
 08 July 2016 
Statins and cirrhosis in Hep B
 07 July 2016 
Predicting food triggers in eosinophilic esophagitis
 07 July 2016 
Extraperitoneal vs transperitoneal colostomy for hernia
 07 July 2016 
Predictors fecal transplant failure in C. diff infection
 06 July 2016 
Therapies for Hep B cure
 06 July 2016 
Hospital volume and liver cancer survival
 06 July 2016 
Adverse events after outpatient colonoscopy
 05 July 2016 
Colorectal surgery and dialysis
 05 July 2016 
Exercise and gastroesophageal reflux
 05 July 2016 
Non-invasive scoring systems for fibrosis in NAFLD
 04 July 2016 
Autoimmunity in eosinophilic esophagitis and families
 04 July 2016 
Rectal cancer surgery checklist
 04 July 2016 
Guidelines on PPI and NSAID prescription

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us